Ongoing Phase 2 Clinical Trial of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Stage 1 and Stage 2 Results. EHA 2017.
Ongoing Phase 2 Clinical Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Stage 1 and Stage 2 Results. EHA 2017. Clinical – Poster
Results From Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2016
Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2016. Clinical – Oral Presentation
Results From Ongoing Phase 2 Trial of SL-401 as Consolidation Therapy in Patients With Acute Myeloid Leukemia (AML) in Remission With High Relapse Risk Including Minimal Residual Disease (MRD)
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). ASH 2016. Clinical – Oral Presentation
Results From Ongoing Phase 2 Trial of SL-401 in Patients With Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. ASH 2016
Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. ASH 2016. Clinical – Poster
Results From Ongoing Phase 1/2 Trial of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Clinical — On-line Abstract
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1)
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro. ASH 2016. Poster
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model Oral Presentation
SL-401, a Novel IL-3R/CD123-Directed Agent Targets Stem-Like Cells in Multiple Myeloma
SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-Like Cells in Multiple Myeloma Poster
Results From Ongoing Phase 2 Registration Study of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Results From Ongoing Phase 2 Registration Study Of SL-401 In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2016. Abstract
Results From Phase 2 Registration Trial of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing
Results From Phase 2 Registration Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing. ASCO 2016. Abstract